Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7921 AL 7935

Initial Real-World Evidence for Lecanemab in the United States

Brixner DI, Zhao C, Toyosaki H, Frech FH, Rosenbloom MH.

Drugs Aging. 2026 Jan;43(1):69-76. doi: 10.1007/s40266-025-01261-x. Epub 2025 Oct 29.

The effects of Lithium on Beta-amyloid deposition and tau phosphorylation: A systematic review

Xiao K, Sayed H, Xing J, Zhang XY, Ai J, Kirichek E, Le GH, Wong S, Valentino K, Teopiz KM, Vinberg M, Rosenblat JD, Lo HKY, Zhang MC, McIntyre RS.

J Affect Disord. 2026 Feb 15;395(Pt A):120721. doi: 10.1016/j.jad.2025.120721. Epub 2025 Nov 17.

Multi-ancestry meta-analysis identifies genetic modifiers of age-at-onset of Alzheimer's disease at known and novel loci

Blue EE, Broome J, Xue D, Kingston H, Chapman NH, Gogarten S; Alzheimer's Disease Genetics Consortium (ADGC); Naj AC, Wijsman EM.

Alzheimers Dement. 2025 Sep;21(9):e70489. doi: 10.1002/alz.70489.

Efficacy of probiotic supplementation in influencing cognitive function in Alzheimer's disease: A systematic review and meta-analysis

Liu W, Guo J, Dong Y, Li J, Wang Y.

J Food Sci. 2025 Jul;90(7):e70037. doi: 10.1111/1750-3841.70037.

Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial

Haaland B, Dickson SP, Santana AF, Tanzi RE, Dubois B, Peters O, Grimmer T, Christensen J, Mallinckrodt C, Schneeberger A, Hendrix SB.

J Alzheimers Dis. 2025 Nov;108(1):234-242. doi: 10.1177/13872877251375985. Epub 2025 Sep 15.

Synthetic control methods for n-of-1 and parallel-group trials in Alzheimer's disease: A proof-of-concept study using the I-CONECT

Wu CY, Chen L, Dickson JR, Zhang B, Arnold SE, Dodge HH.

Alzheimers Dement. 2025 Jul;21(7):e70460. doi: 10.1002/alz.70460.

Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M(1) positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants

Conley AC, Key AP, Blackford JU, Russell JK, Albert KM, Gong X, Bubser M, Rook JM, Conn PJ, Lindsley CW, Jones CK, Newhouse PA.

Alzheimers Res Ther. 2025 Jul 1;17(1):144. doi: 10.1186/s13195-025-01798-4.

Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

Corraliza-Gomez M, Vargas-Soria M, Garcia-Alloza M.

Mol Neurodegener. 2025 Oct 27;20(1):112. doi: 10.1186/s13024-025-00894-1.

Effect of the probiotic Escherichia coli Nissle 1917 on serum levels of NADPH oxidase-2 and lipopolysaccharide in patients with Alzheimer's disease

Loffredo L, Alfano AR, Ettorre E, Desideri G, Carnevale R, Forte M, Maglione V, Bartimoccia S, Castellani V, Totè CM, Pignatelli P, Violi F; Neurodegenerative Disease study group.

J Alzheimers Dis. 2025 Jul;106(2):774-782. doi: 10.1177/13872877251345157. Epub 2025 Jul 1.

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study

Sol O, Mermoud J, Hallikainen M, Kurl S, Rinne J, Dautzenberg P, Vijverberg EGB, Mummery C, Börjesson-Hanson A, Jonsson M, Ritchie C, Pennington C, Vukicevic M, Gollwitzer E, Fiorini E, Hickman DT, Hliva V, Gray J, Gerasymchuk V, Wagg J, Fournier N, Lê B, Kezic I, Steukers L, Triana-Baltzer G, Theunis C, Streffer J, Kosco-Vilbois M, Pfeifer A, Scheltens P.

EBioMedicine. 2025 Oct;120:105940. doi: 10.1016/j.ebiom.2025.105940. Epub 2025 Sep 18.

Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review

Xing B, Yang J, Hua H, Jiang R.

Medicine (Baltimore). 2025 Jun 6;104(23):e42744. doi: 10.1097/MD.0000000000042744.

Direct hybridization and bioinformatics analysis of circulating microRNAs in patients with Alzheimer's disease under intravenous trehalose treatment

Radbakhsh S, Abrego-Guandique DM, Bacchetti T, Aghaee-Bakhtiari SH, Mahmoudi A, Manteghi AA, Bazyari MJ, Cione E, Ferretti G, Sahebkar A.

Brain Res. 2025 Jun 15;1857:149607. doi: 10.1016/j.brainres.2025.149607. Epub 2025 Apr 3.

A review of the TGF-β1 pathway in Alzheimer's disease and depression: Possible restoration potential of antidepressants

Eleni I, Theofanis V, Zisis B, Eleni S.

Neuroscience. 2025 Oct 15;585:429-440. doi: 10.1016/j.neuroscience.2025.09.010. Epub 2025 Sep 12.

Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)

Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg PB, Herrmann N, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Mintzer J, Lanctôt KL.

Int Psychogeriatr. 2025 Mar;37(2):100012. doi: 10.1016/j.inpsyc.2024.100012. Epub 2024 Dec 4.

Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer's disease

Budda B, Mitra A, Park L, Long H, Kurnellas M, Bien-Ly N, Estacio W, Burgess B, Chao G, Schwabe T, Paul R, Kenkare-Mitra S, Rosenthal A.

Alzheimers Res Ther. 2025 Jul 25;17(1):174. doi: 10.1186/s13195-025-01817-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias